Iovance Biotherapeutics Stock Price

-0.52 (-2.26%)
Upgrade to Real-Time
Regular Market


52 Week Range


Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Iovance Biotherapeutics Inc IOVA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.52 -2.26% 22.53 13:47:45
Open Price Low Price High Price Close Price Prev Close
23.03 22.19 23.30 23.05
Bid Price Ask Price Spread News
22.50 22.53 0.03 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
8,157 805,317 $ 22.62 $ 18,215,580 - 15.88 - 54.2081
Last Trade Time Type Quantity Stock Price Currency
13:48:22 5 $ 22.53 USD


Draw Mode:

Iovance Biotherapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 3.44B 152.85M 127.68M $ - $ - -1.89 -12.50
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 288.68k 13.60%

more financials information »

Iovance Biotherapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical IOVA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week22.0524.2321.7523.401,397,8590.482.18%
1 Month27.6128.0021.6724.891,784,489-5.08-18.4%
3 Months31.8832.1015.8821.413,893,614-9.35-29.33%
6 Months46.5553.0415.8826.162,788,998-24.02-51.6%
1 Year27.843554.208115.8829.732,043,163-5.31-19.08%
3 Years14.0054.20817.2624.561,706,8408.5360.93%
5 Years8.2554.20814.4522.391,230,16314.28173.09%

Iovance Biotherapeutics Description

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company. The company focused on the development and commercialization of cell therapies as novel cancer immunotherapy products designed to harness the power of a patient's immune system to eradicate cancer cells. It's lead pipeline candidate, LN-145, is an adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) to treat patients with refractory metastatic melanoma.

Your Recent History
Iovance Bi..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.